REMIT-UC: Real World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis.
Christopher MaRemo PanaccioneYasi XiaoYuvan KhandelwalSanjay K MurthyEmily C L WongNeeraj NarulaCatherine TsaiFarhad PeeraniMarica Reise-FilteauBrian BresslerSamantha Y StarkeyDustin LoomesRocio SedanoVipul JairathTalat BessissowPublished in: The American journal of gastroenterology (2022)
One-third of UC patients treated with tofacitinib achieved clinical remission with few serious adverse events. However, half of patients lost response with de-escalation, which was only partially recaptured with increasing the maintenance dose. Those with negative prognostic factors should be counselled about the risks and benefits of continuing high dose tofacitinib.
Keyphrases
- ulcerative colitis
- prognostic factors
- rheumatoid arthritis
- high dose
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- open label
- disease activity
- peritoneal dialysis
- risk assessment
- stem cell transplantation
- high intensity
- systemic lupus erythematosus
- patient reported outcomes
- climate change